Evidence Hub

Intravenous proton pump inhibitors vs oral potassium competitive acid blockers before endoscopic treatment of bleeding peptic ulcers

Lim NR, Chung WC

World journal of gastrointestinal endoscopy, 2025

105 participants

Abstract

BACKGROUND: The use of proton pump inhibitors (PPIs) with the intent of reducing gastric acidity to the desired therapeutic level for treating bleeding peptic ulcer still has several limitations.

AIM: To compare intravenous PPIs and oral potassium competitive acid blockers (PCABs) administered prior to endoscopic treatment of bleeding peptic ulcers.

METHODS: This retrospective study involved 105 consecutive patients with non-variceal upper gastrointestinal bleeding (treated August 2023 to February 2024). Prior to emergency endoscopy, patients received either intravenous PPI (pantoprazole 80 mg bolus) or oral PCAB (tegoprazan 50 mg single-dose). Severity of bleeding was assessed using the Glasgow-Blatchford, Rockall, and AIMS65 scoring systems. Patients with severe comorbidities were excluded. Primary outcomes included need for therapeutic endoscopic intervention and occurrence of re-bleeding. Multivariate logistic regression was performed to adjust for potential confounding factors.

RESULTS: Total of the 105 patients, 61 received intravenous PPI injection and 44 received oral PCAB prior to emergency endoscopy. To minimize selection bias, bleeding severity was assessed using the Glasgow-Blatchford, Rockall and AIMS65 scores, with no statistically significant differences observed between the two groups. During emergency endoscopy performed within 48 hours, ulcer bed status was classified according to the Forrest classification. The proportion of lesions graded IIa or higher…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free